Merck Collaborates with Dragonfly to Develop and Commercialize Novel Therapies Utilizing TriNKET Platform

Shots:

• Dragonfly to receive ~ $47.5M up front, equity investment, development & commercial milestones along with royalties on sales of approved therapies
• Merck to get an option to license exclusive IP rights for multiple candidates developed using Dragonfly’s TriNKET technology platform for new targets in oncology, infectious disease, and immune disorders
• Dragonfly’s TriNKET technology act by harnessing the body’s innate immune system to bring breakthrough cancer therapies to the patients

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Dragonfly